AstraZeneca localized in Russia production of ticagrelor

Company AstraZeneca localized at its own plant in Kaluga region manufacture of the finished dosage form of ticagrelor 90 mg for the treatment of patients with acute coronary syndrome (ACS).

Ticagrelor (trade name of Brilinta) is included in the list of essential drugs and included in the standards of specialized medical care for patients with acute myocardial infarction (with ST-segment elevation) and unstable angina, acute and recurrent myocardial infarction (without ST-segment elevation). Localization of production of the drug is responsible for several strategic challenges facing the national system of health: contributing to the implementation of state plans for import substitution in the fight against cardiovascular disease and enhances patient access to effective treatment.

According to the state program “Development of pharmaceutical and medical industry”, adopted in 2009, 2020, 9 out of 10 packages of vital and essential medicinal products at the Russian market must be produced, and the localization of production accelerates the achievement of this goal.

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]